Market News AIOpen the app

Inhibrx Biosciences shared new clinical results showing a 62.7% response rate for its ozekibart treatment.

TrialRead the original at SEC EDGAR
Good for INBX

Inhibrx reported a 62.7% response rate and 86.3% disease control rate with ozekibart plus chemotherapy. These results compare favorably with past treatment results, though ozekibart is still being tested for Ewing sarcoma.

INBX · Inhibrx Biosciences, Inc.

AI read · Good for INBX

The AI's read

The response rate compares with 15% to 30% for irinotecan and temozolomide alone. Median time before disease worsened was 6.0 months, versus 3 to 4 months with those drugs alone. Responses lasted more than 6 months in 18 patients, and the company reported no unexpected liver injury. Still, ozekibart is being tested for Ewing sarcoma, so these results do not establish approval or benefit for every patient.

Get alerts for INBX

Follow Inhibrx Biosciences, Inc. (INBX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for INBX
Free on the App Store and Google Play, or on the web.